PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort-Reference-Cited by-同舟云学术

PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

Published:2022-02 Issue: Volume:146 Page:112519
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Vicente-Valor Juan,García-González Xandra,Ibáñez-García Sara,Durán-García María Esther,de Lorenzo-Pinto Ana,Rodríguez-González Carmen,Méndez-Fernández Irene,Percovich-Hualpa Juan Carlos,Herranz-Alonso Ana,Sanjurjo-Sáez María

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference60 articles.

1. Cardiovascular disease in Europe: epidemiological update 2016;Townsend;Eur. Heart J.,2016

2. Eurostat. Cardiovascular diseases statistics [Internet]. 2020 [cited 2021 Jun 13]. Available from: 〈https://ec.europa.eu/eurostat/statistics-explained/index.php/Cardiovascular_diseases_statistics#Deaths_from_cardiovascular_diseases〉.

3. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur. Heart J.,2020

4. Interpretation of the evidence for the efficacy and safety of statin therapy;Collins;Lancet Lond. Engl.,2016

5. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis;Silverman;JAMA,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal Anti-PCSK9 Antibodies: Real-World Data;Journal of Clinical Medicine;2024-08-03

2. Targeting Allosteric Site of PCSK9 Enzyme for the Identification of Small Molecule Inhibitors: An In Silico Drug Repurposing Study;Biomedicines;2024-01-26

3. Unraveling Potential Sex‐Specific Effects of Cardiovascular Medications on Longevity Using Mendelian Randomization;Journal of the American Heart Association;2023-12-19

4. Sex differences in efficacy and safety of PCSK9 monoclonal antibodies: A real-world registry;Atherosclerosis;2023-11

5. Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study;Journal of Cardiovascular Medicine;2023-09-29